TetraQ, the commercial arm of The University of Queensland’s Centre for Integrated Preclinical Drug Development (CIPDD), has appointed Kris Dyszynski to the position of Business Development, North America.
As one of Australia’s leading preclinical contract research organisations (CRO’s), TetraQ (a registered business of UniQuest Pty Ltd) believes establishing a North American based development officer will help forge new business relationships and opportunities.
TetraQ CEO Maree Smith said the Queensland Smart State Entrepreneur-In- Residence Grant, worth $225,000 and announced recently by Treasurer Andrew Fraser, made the appointment possible.
“Mr Dyszynski’s new role will be undertaking business development activities for TetraQ within North America and identifying collaborative research and development activities for the CIPDD."
“At TetraQ we sit in the translational research space; we assist universities, small biotech and pharmaceutical companies in getting potential drugs from the laboratory bench to the market,” she said.
“We perform preclinical drug trials, showing these drugs are efficacious – they do what the company says they do – and that they’re safe to go on to human trials.
“This is a great opportunity for TetraQ and the CIPDD to establish a tangible presence within North America that further builds on TetraQ’s existing international reach and activities.”
Mr. Dyszynski has over 25 years of business experience in the biotechnology industry, with global responsibilities. Prior to joining TetraQ, Mr. Dyszynski was based in the US as Vice President, Business Development for Australian company Alchemia Limited.
Mr Dyszynski said his new role gave TetraQ someone on the ground in North America, which enjoyed a significant proportion of the global R & D spend on preclinical development – worth almost $4 billion in 2008.
“There’s no real Australian Preclinical Contract Research Organisation (CRO) footprint in North America at present,” he said, “which means TetraQ can really make an impact.
“TetraQ is at a distinct advantage in that it can offer an attractive value proposition for clients in North America by providing a high quality, good value, personalised service which is tailored to meet their specific needs.
“So we have the opportunity here to bring a lot of preclinical drug development business into Australia.”
TetraQ expects the appointment will also facilitate knowledge diffusion between Mr. Dyszynski, who’s located in the US, and TetraQ and its other University of Queensland stakeholders, with further opportunities arising during his regular visits to Australia.
About TetraQ
TetraQ is the first contract research organisation in Australia to provide integrated preclinical services to the global pharmaceutical and biotechnology industries.
Providing a broad range of preclinical services and advice to companies that are in the early stages of drug development, TetraQ can assist in bridging the gap between drug discovery and early stage clinical trials. TetraQ draws on the expertise of four leading specialists in preclinical drug development. Its team of highly experienced scientists is supported by a dedicated Commercial Manager, operations Manager, Sales & Services Manager and a Quality Assurance Manager.
TetraQ has built world-class facilities to provide its extensive and expanding range of services. This has been enabled by $8.1M in investment funds from the Queensland Government’s Smart State Research Facilities Fund, along with significant cash and in-kind support from The University of Queensland and its supporting partners, Q-Pharm Pty Ltd and The Queensland Institute of Medical Research.
Formed in 2005 and located at The University of Queensland (UQ) in Brisbane, TetraQ is the commercial arm of the Centre for Integrated Preclinical Drug Development. This Centre is the focal point of research and training excellence in the field of preclinical drug development. TetraQ is also a registered business of UniQuest Pty Ltd, the main technology transfer company of UQ.
About UniQuest Pty Limited
Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia’s largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. The company’s charter is to identify, package and commercialise research-based technologies, expertise and facilities to the community, industry, business and government. It has created more than 60 companies, and since 2000 UniQuest and its start-ups have raised a quarter of a billion dollars to take UQ technologies to market. Sales of products using UQ technology and licensed by UniQuest are now running at $5.2 billion per year.
UniQuest now commercialises research, expertise and technologies developed at The University of Queensland, University of Wollongong, University of Technology Sydney, University of Tasmania, James Cook University and the Mater Medical Research Institute.
As one of Australia’s leading preclinical contract research organisations (CRO’s), TetraQ (a registered business of UniQuest Pty Ltd) believes establishing a North American based development officer will help forge new business relationships and opportunities.
TetraQ CEO Maree Smith said the Queensland Smart State Entrepreneur-In- Residence Grant, worth $225,000 and announced recently by Treasurer Andrew Fraser, made the appointment possible.
“Mr Dyszynski’s new role will be undertaking business development activities for TetraQ within North America and identifying collaborative research and development activities for the CIPDD."
“At TetraQ we sit in the translational research space; we assist universities, small biotech and pharmaceutical companies in getting potential drugs from the laboratory bench to the market,” she said.
“We perform preclinical drug trials, showing these drugs are efficacious – they do what the company says they do – and that they’re safe to go on to human trials.
“This is a great opportunity for TetraQ and the CIPDD to establish a tangible presence within North America that further builds on TetraQ’s existing international reach and activities.”
Mr. Dyszynski has over 25 years of business experience in the biotechnology industry, with global responsibilities. Prior to joining TetraQ, Mr. Dyszynski was based in the US as Vice President, Business Development for Australian company Alchemia Limited.
Mr Dyszynski said his new role gave TetraQ someone on the ground in North America, which enjoyed a significant proportion of the global R & D spend on preclinical development – worth almost $4 billion in 2008.
“There’s no real Australian Preclinical Contract Research Organisation (CRO) footprint in North America at present,” he said, “which means TetraQ can really make an impact.
“TetraQ is at a distinct advantage in that it can offer an attractive value proposition for clients in North America by providing a high quality, good value, personalised service which is tailored to meet their specific needs.
“So we have the opportunity here to bring a lot of preclinical drug development business into Australia.”
TetraQ expects the appointment will also facilitate knowledge diffusion between Mr. Dyszynski, who’s located in the US, and TetraQ and its other University of Queensland stakeholders, with further opportunities arising during his regular visits to Australia.
About TetraQ
TetraQ is the first contract research organisation in Australia to provide integrated preclinical services to the global pharmaceutical and biotechnology industries.
Providing a broad range of preclinical services and advice to companies that are in the early stages of drug development, TetraQ can assist in bridging the gap between drug discovery and early stage clinical trials. TetraQ draws on the expertise of four leading specialists in preclinical drug development. Its team of highly experienced scientists is supported by a dedicated Commercial Manager, operations Manager, Sales & Services Manager and a Quality Assurance Manager.
TetraQ has built world-class facilities to provide its extensive and expanding range of services. This has been enabled by $8.1M in investment funds from the Queensland Government’s Smart State Research Facilities Fund, along with significant cash and in-kind support from The University of Queensland and its supporting partners, Q-Pharm Pty Ltd and The Queensland Institute of Medical Research.
Formed in 2005 and located at The University of Queensland (UQ) in Brisbane, TetraQ is the commercial arm of the Centre for Integrated Preclinical Drug Development. This Centre is the focal point of research and training excellence in the field of preclinical drug development. TetraQ is also a registered business of UniQuest Pty Ltd, the main technology transfer company of UQ.
About UniQuest Pty Limited
Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia’s largest and most successful university commercialisation groups, benchmarking in the top tier of technology transfer worldwide. The company’s charter is to identify, package and commercialise research-based technologies, expertise and facilities to the community, industry, business and government. It has created more than 60 companies, and since 2000 UniQuest and its start-ups have raised a quarter of a billion dollars to take UQ technologies to market. Sales of products using UQ technology and licensed by UniQuest are now running at $5.2 billion per year.
UniQuest now commercialises research, expertise and technologies developed at The University of Queensland, University of Wollongong, University of Technology Sydney, University of Tasmania, James Cook University and the Mater Medical Research Institute.
